SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) today announced preliminary data of Hepatitis-C (HCV) infected patients treated with the Aethlon Hemopurifier®, a medical device designed to assist the immune response in combating infectious disease. The HCV treated patients were among end-stage renal disease (kidney dialysis) patients enrolled in human safety studies being conducted at the Fortis Hospital, in Delhi, India.
